FAB-2022-10562
β-Carboline derivatives have a wide range of biological effects such as antiviral, antitumor and antimalarial and are therefore important compounds for drug development. In this study, the effect of some β-carboline derivatives on glucose 6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6PGD), and antibacterial activities were investigated. For this purpose, affinity chromatography was used to separate G6PD and 6PGD from human erythrocytes with a specific activity of 1.96 EU/ml protein and 4.569 EU/ml protein, respectively and then in vitro effects of compounds were assayed. It was found that only 1-Isopropyl-2,3,4,9-tetrahydro-1H-beta-carboline, among the selected β-Carboline derivatives, inhibited G6PD with an IC50 value of 31.2 µM. It was determined that other derivatives did not have any effect on G6PD and 6PGD activities. Besides antibacterial effects of compounds were examined and compounds were found effective against Escherichia coli, Klebsiella pneumoniae, and Acinetobacter haemolyticus. Molecular docking study of isopropyl-2,3,4,9-tetrahydro-1H-beta-carboline molecule to the hG6PD (6E08) receptor was performed and the estimated binding energy was determined as -6.97 kcal/mol. According to the results of antibacterial studies, compounds were docked into some specific proteins of microorganisms as well and possible interactions between receptors and derivatives were discussed.
6-phosphogluconate dehydrogenase Antibacterial structure-activity relationship glucose 6-phosphate dehydrogenase molecular docking
Atatürk University-Scientific Research Projects
FAB-2022-10562
Primary Language | English |
---|---|
Subjects | Structural Biology |
Journal Section | Research Articles |
Authors | |
Project Number | FAB-2022-10562 |
Early Pub Date | June 2, 2025 |
Publication Date | June 24, 2025 |
Submission Date | February 28, 2025 |
Acceptance Date | May 16, 2025 |
Published in Issue | Year 2025 Volume: 9 Issue: 1 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.